EP
HQL

Eudaimonia Partners’s abrdn Life Sciences Investors HQL Stock Holding History

Eudaimonia Partners’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$142K Buy
+10,434
New +$144K 0.03% 253
2023
Q1 		– Sell
-13,790
Closed -$196K – 367
2022
Q4 		$196K Buy
13,790
+548
+4% +$7.94K 0.05% 322
2022
Q3 		$181K Buy
13,242
+1,477
+13% +$22.1K 0.05% 319
2022
Q2 		$167K Sell
11,765
-263
-2% -$3.97K 0.03% 370
2022
Q1 		$199K Buy
+12,028
New +$207K 0.03% 385
2021
Q2 		– Sell
-6,729
Closed -$133K – 795
2021
Q1 		$133K Sell
6,729
-723
-10% -$14.9K 0.03% 412
2020
Q4 		$147K Buy
7,452
+142
+2% +$2.62K 0.03% 359
2020
Q3 		$129K Buy
7,310
+165
+2% +$2.96K 0.03% 351
2020
Q2 		$128K Buy
7,145
+127
+2% +$2.18K 0.05% 309
2020
Q1 		$105K Sell
7,018
-11,273
-62% -$185K 0.05% 323
2019
Q4 		$319K Buy
+18,291
New +$300K 0.13% 182

Other funds holding HQL

SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
AIA
Absolute Investment Advisers Rosemary Beach, Florida $852M AUM 0.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
RL
RPO LLC Stamford, Connecticut $32.3M AUM 14.17% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return

Eudaimonia Partners's HQL Position: Q1 2024 in Review

Eudaimonia Partners opened a new position in abrdn Life Sciences Investors (HQL) in Q1 2024: 10,434 shares worth $142K. The stake represents 0.03% of the portfolio and ranks #253 among its holdings. This is a return to the name: Eudaimonia Partners previously reported a position in HQL as recently as Q4 2022.

Eudaimonia Partners first reported a position in HQL in Q4 2019 and has held it in 11 quarters since. The position peaked at $319K in Q4 2019. 79 funds tracked by Wall St. Rank hold HQL as of Q1 2024.

  • Eudaimonia Partners held 10,434 shares of abrdn Life Sciences Investors worth $142K as of Q1 2024.
  • abrdn Life Sciences Investors was a new Eudaimonia Partners position in Q1 2024.
  • abrdn Life Sciences Investors made up 0.03% of Eudaimonia Partners's portfolio in Q1 2024, its #253 holding.
  • Eudaimonia Partners first reported a position in abrdn Life Sciences Investors in Q4 2019 and has held it in 11 quarters since.
  • Eudaimonia Partners's abrdn Life Sciences Investors position peaked at $319K in Q4 2019.
  • 79 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q1 2024.

Based on Eudaimonia Partners's 13F filing for Q1 2024, filed 25 Apr 2024.